Finanzen von Inozyme Pharma Inc (INZY)INZYInozyme Pharma Inc

Evaluating the bottom line, Inozyme Pharma Inc maintains a gross margin of N/A. This metric reflects the company's pricing power and manufacturing efficiency. Further down the income statement, the operating margin stands at N/A, while the net margin is N/A. These profitability ratios, combined with a Return on Equity (ROE) of -141.69%, provide a clear picture of how effectively INZY converts its operational activities into shareholder value.

In the context of the broader market, INZY competes directly with industry leaders such as TNXP and ANNX. With a market capitalization of N/A, it holds a significant position in the sector. When comparing efficiency, INZY's gross margin of N/A stands against TNXP's 94.81% and ANNX's N/A. Such benchmarking helps identify whether Inozyme Pharma Inc is trading at a premium or discount relative to its financial performance.